Assessment of α-amylase and α-glucosidase inhibitory potential of Citrus reticulata peel extracts in hyperglycemic/hypoglycemic rats.

Diabetes mellitus is a metabolic disorder of carbohydrate metabolism. The management of Diabetes mellitus with phytochemicals is hallmark of this research. Citrus species are known for their health benefits and are used as traditional food in South East Asia. The total phenolic content of peels was analyzed using different solvents, while Gallic acid was used as standard. Both ethanolic, aqueous extracts of Citrus reticulata peel showed good inhibitory activity against amylase (90.67%, 15.33%) and moderate against glucosidase (70.8%, 14.8%), respectively. Sixteen rats were randomly divided into four groups (G1, G2, G3, and G4); G1 is a negative control (water), G4 is a positive control (Acarbose), while other two are experimental groups like G2 (fed with 100 mL and 20 mg/mL in hypoglycemic and hyperglycemic trials) and G3 fed with 200 mL and 40 mg/mL in hypoglycemic and hyperglycemic trials. A significant effect of treatments and value of time was found in hyperglycemic rats. Ethanolic extract showed a significant reduction in blood glucose levels in hypoglycemic (overnight fasting) rats which was comparable to the positive control. These results suggest that C. reticulata peels can contribute as a useful food ingredient as a potential antihyperglycemic agent in managing type 2 diabetes mellitus. In future, C. reticulata peel will be a good candidate for pharmaceutical industry.

Enhanced Efficacy of Direct-Acting Antivirals in Hepatitis C Patients by Coadministration of Black Cumin and Ascorbate as Antioxidant Adjuvants.

The widespread adaptation of a new generation of direct-acting antiviral agents (DAAs) unveils a superlative effect in the eradication of the hepatitis C virus (HCV). However, this therapy has been reported to exhibit vigorous side effects that pose a risk in fleet recovery. This study was conducted to investigate the efficacy of DAAs: sofosbuvir (SOF) and ribavirin (RBV), along with black cumin (BLC) and ascorbate (ASC), as adjuvants on hematological parameters; oxidative stress markers such as total antioxidant status (TAS), superoxide dismutase (SOD), reduced (GSH) and oxidized (GSSG) glutathione (GSH), gamma-glutamyl transferase (GGT), and malondialdehyde (MDA); liver function markers such as aspartate transaminase (AST), alanine aminotransferase (ALT), bilirubin, and alkaline phosphatase (ALP); and viral load with determined genotypes. HCV-infected patients (n = 30) were randomly divided into two equal groups: control group (n = 15) and treatment group (n = 15). The control group was subjected only to SOF and RBV (400 mg each/day). Synergistically, the treatment group was administered with adjuvant therapy of BLC (250 mg/day) and ASC (1000 mg/day) along with DAAs (400 mg each/day) for 8 weeks. All selected patients were subjected to sampling at pre- and posttreatment stages for the assessment of defined parameters. The data revealed that the BLC/ASC adjuvant therapy boosted the efficacy of DAAs by reducing the elevated levels of liver markers such as AST, ALT, ALP, and bilirubin in the treatment group compared with those in the control group (P > 0.05). The adjuvant therapy synchronously showed an ameliorating effect on hematological parameters. The SOF/RBV with adjuvant therapy also demonstrated an increasing effect in the activity of SOD, TAS, and GSH and a decreasing effect for GSSG, GGT, and malondialdehyde (MDA; P > 0.05) followed by curtailing a RT-PCR-quantified viral load. Our findings provide evidence that systemic administration of BLC/ASC efficiently alleviates hematological, serological, and antioxidant markers as well as the viral load in hepatitis C patients. This highlights a potentially novel role of BLC and ASC in palliating hepatitis C.

Effect of Prebiotic Galacto-Oligosaccharides on Serum Lipid Profile of Hypercholesterolemics.

The present study focused on the role of galacto-oligosaccharides (GOS) against the development of hypercholesterolemia. In the current research, GOS synthesized from lactose solution were fed to hypercholesterolemic female Sprague-Dawley rats. Negative control group (G1) was fed on standard basal diet alone. Positive control group (G5) was fed on inulin (154 mg/250 g body weight), while treatment groups G2, G3 and G4 received 110 mg, 154 mg and 198.4 mg/250 g body weight, respectively, of GOS along with high-fat diet for a period of 60 days. Findings from this study revealed that animals belonging to prebiotic GOS (G2, G3 and G4)-fed group showed significantly decreased serum triglycerides, total cholesterol, LDL cholesterol and VLDL cholesterol as compared to control group (G0). The groups which were fed on different doses of GOS revealed a significant reduction in TC, TG, LDL, and VLDL levels and an increase in HDL level corresponding to the reference group that was fed on inulin, while G1 negative control group revealed increased levels of TC, TG, LDL and VLDL. In contrast to positive control group G5 (154 mg inulin), all doses of GOS lowered serum TC, TG and LDL-C and raised HDL-C; however, G4 (198.4 mg) proved to be more effective. Hence, GOS proved to be supportive in preventing hypercholesterolemia leading cause of cardiovascular disease and atherosclerosis. This study reported a significant reduction of serum TC, TG and LDL-C in female rats for 60 days as compared to control. Conclusively, GOS were found to be worthless against hypercholesterolemia.

Gender differences on bioavailabity of ofloxacin.

BACKGROUND: The fluoroquinolones are currently enjoying extensive worldwide clinical applications because of their good bioavailability and pharmacokinetic profile. Investigation into several aspects of the pharmacokinetic of all clinically relevant fluoroquinolones, have been carried out notably in Europe, USA and Japan. In view of the 'geonetical' (geographical influences on genetics-pharmacogenetics) differences, it is important that for the optimal therapeutic outcome, biodisposition studies on drugs are better conducted in the population and environments where wide and extensive use of the drug is anticipated. The Objectives of study were to see the pharmacokinetic parameters in healthy young male and female volunteers. This comparative study was conducted King Edward Medical University, Lahore, Pakistan, from July 2005 to December 2005. METHOD: In Pakistan where the use of antibiotics is more frequent by the general practitioners it is important to elucidate certain dose parameters it is also noticed that side effects are more in females than males so present study is conducted to calculate any differences in bioavailability on the basis of sex. The pharmacokinetic parameters of ofloxacin were determined in each of the clinically health eight young girls and boys (mean age 23.9 and 25.1 years, respectively) following a single oral dose of 400 mg tablet. The method adopted was microbiological assay. RESULTS: The blood samples collected at predetermined time intervals after drug administration revealed almost twice as high concentration of the drug in plasma of the girls than that in the boys. The pharmacokinetic parameters revealed significantly (p < 0.01) higher values for area under curve (AUC) and C(max) and lower total body clearance (TBC) and volume of distribution in the girls than in the boys. CONCLUSION: The gender differences in pharmacokinetic parameters indicate that the dose adjustment should be considered in male and female.